Cadila Healthcare Chairman Pankaj Patel On The Potential For Consolidation In The Indian Industry: An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Executive Summary
Every player wants to continue to work rather than take a back seat. Unless that mindset comes to India, consolidation within Indian players is tough to find, says Patel.
You may also be interested in...
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015
AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015
Bayer And Cadila Pool Products To Form Equal Stake JV For India Market
MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise
India's Health Minister Hits Out At Buyouts By Foreign Drug Makers; Are Investment Restrictions In The Cards?
MUMBAI - India's health minister Ghulam Nabi Azad has reiterated his concerns about the growing dominance of multinational companies in the Indian market, pressing the commerce ministry to disallow full or majority ownership of Indian companies by large foreign drug makers